Aegis Therapeutics Celebrates 10th Anniversary

Aegis Therapeutics Celebrates 10th Anniversary 
SAN DIEGO, CA -- (Marketwired) -- 10/28/13 --  Aegis Therapeutics LLC
is proud to announce it is celebrating its 10-year anniversary on
October 31, 2013.  
Aegis was founded by a renowned group of successful biotech
entrepreneurs from the San Diego area to commercialize proprietary
technologies that solve some of the most pressing drug delivery
problems for small molecule drugs and biotherapeutics. These patented
technologies are marketed under the Intravail(R) and ProTek(R)
Aegis' Intravail(R) noninvasive delivery technology allows current
injected drugs to be administered noninvasively either by a metered
nasal spray or orally, dramatically increasing drug absorption and
speeding onset of action, which is particularly important for
treatment of certain clinical conditions such as pain, nausea,
emesis, convulsive and other CNS disorders, spasticity, and the like
where rapid relief is critical to patient comfort and recovery.  
Aegis' ProTek(R) technology stabilizes biotherapeutics such as
monoclonal antibodies, preventing protein aggregation and oxidative
damage caused by the widely used current stabilizers called
polysorbates, which lead to unwanted immunogenicity that limits or
obviates the usefulness of this very important class of drugs.   
Aegis' licensees include some of the world's premier pharmaceutical
and biotech companies (five of the top 10 largest pharmaceutical
companies and two of the top 10 largest generics companies, along
with many public and private biotech companies) including Hoffmann-La
Roche Inc.; Dr. Reddy's Laboratories, Ltd; Biodel, Inc.; and
Neurelis, Inc.  
"The last 10 years have been filled with challenges, achievements,
growth and new product introductions," said Edward T. Maggio, Ph.D.,
Aegis co-founder and Chief Executive Officer. "Our success has been
the direct result of our partner's efforts and their belief in Aegis'
technologies as they successfully incorporate these technologies in
their product development activities to improve the health and
quality of life for patients."  
We are pleased with our growth and accomplishments to date. Aegis was
founded in 2003 obtaining an exclusive worldwide license from the
University of Alabama Birmingham Research Foundation to U.S. Patent
5,661,130 for non-invasive delivery of peptides and proteins
currently marketed under the Intravail(R) brand. Since then Aegis has
significantly expanded its patent portfolio providing protection for
partner programs with 13 additional issued U.S. and foreign patents
expiring between 2026 and December 2029 and well over 50 additional
U.S. and foreign patent applications pending covering drug
formulations and methods of treatment for a broad range of clinical
conditions. Since our initial funding 2004 of a little over $1
million, Aegis has been profitable, making distributions back to its
Examples of our partners successful innovative applications include a
nasal sumatriptan spray that achieves therapeutic levels in 2 to 3
minutes compared to 60 to 120 minutes for the existing nasal and oral
formulations (roughly 20 times faster) to provide relief from
migraine headaches, and a fast acting diazepam nasal spray developed
initially by San Diego based Neurelis, and now in conjunction with
Biotie Therapies, a leading drug development company focused
primarily on products for neurodegenerative and psychiatric
disorders. The diazepam nasal spray is being developed to provide
immediate treatment for epilepsy patients who experience unexpected
seizures, circumventing the delayed treatment and high cost of
emergency room trips which comprise the current standard of care in
the US.  
About Aegis Therapeutics  
Aegis Therapeutics LLC is a drug delivery technology company
commercializing its patented drug delivery and drug formulation
technologies through product-specific licenses. Aegis' Intravail(R)
drug delivery technology enables the non-invasive delivery of a broad
range of protein, peptide and non-peptide drugs that can currently
only be administered by injection, via the oral, buccal, and
intranasal administration routes, and with high bioavailability.
Aegis' ProTek(R) excipients stabilize, prevent aggregation, and
reduce unwanted immunogenicity of protein and peptide therapeutics
while avoiding the oxidative damage caused by polysorbate
For more information about Aegis, please visit: 
Ralph Barry 
Chief Business Officer
Aegis Therapeutics LLC 
1-858-618-1400 Ext. 102 
Press spacebar to pause and continue. Press esc to stop.